Souders Financial Advisors lowered its position in Abbott Laboratories (NYSE:ABT - Free Report) by 32.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 21,511 shares of the healthcare product maker's stock after selling 10,521 shares during the quarter. Souders Financial Advisors' holdings in Abbott Laboratories were worth $2,853,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors also recently made changes to their positions in the company. J.W. Cole Advisors Inc. grew its stake in shares of Abbott Laboratories by 52.3% in the 1st quarter. J.W. Cole Advisors Inc. now owns 35,669 shares of the healthcare product maker's stock worth $4,732,000 after purchasing an additional 12,246 shares during the last quarter. BKM Wealth Management LLC grew its stake in shares of Abbott Laboratories by 7.0% in the 1st quarter. BKM Wealth Management LLC now owns 20,747 shares of the healthcare product maker's stock worth $2,752,000 after purchasing an additional 1,352 shares during the last quarter. WNY Asset Management LLC grew its stake in shares of Abbott Laboratories by 2.1% in the 1st quarter. WNY Asset Management LLC now owns 7,332 shares of the healthcare product maker's stock worth $973,000 after purchasing an additional 153 shares during the last quarter. Montag A & Associates Inc. grew its stake in shares of Abbott Laboratories by 2.1% in the 1st quarter. Montag A & Associates Inc. now owns 104,841 shares of the healthcare product maker's stock worth $13,907,000 after purchasing an additional 2,198 shares during the last quarter. Finally, OneAscent Financial Services LLC grew its stake in shares of Abbott Laboratories by 128.8% in the 1st quarter. OneAscent Financial Services LLC now owns 15,610 shares of the healthcare product maker's stock worth $2,066,000 after purchasing an additional 8,786 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.
Abbott Laboratories Trading Up 0.8%
Shares of Abbott Laboratories stock traded up $0.98 on Tuesday, reaching $125.40. 4,939,523 shares of the company's stock were exchanged, compared to its average volume of 6,237,483. The company has a market capitalization of $218.17 billion, a P/E ratio of 15.69, a price-to-earnings-growth ratio of 2.35 and a beta of 0.73. Abbott Laboratories has a 52 week low of $99.92 and a 52 week high of $141.23. The firm's 50-day moving average is $132.98 and its two-hundred day moving average is $129.68. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.27 and a current ratio of 1.78.
Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.83%. The business had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. During the same period in the prior year, the firm posted $1.14 EPS. The firm's quarterly revenue was up 7.4% compared to the same quarter last year. Sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.
Abbott Laboratories Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be paid a $0.59 dividend. The ex-dividend date is Tuesday, July 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.88%. Abbott Laboratories's payout ratio is presently 29.57%.
Insider Transactions at Abbott Laboratories
In other news, Director Sally E. Blount sold 2,600 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total value of $337,116.00. Following the sale, the director directly owned 34,058 shares of the company's stock, valued at $4,415,960.28. The trade was a 7.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.46% of the stock is currently owned by insiders.
Analysts Set New Price Targets
A number of analysts have commented on ABT shares. William Blair raised shares of Abbott Laboratories to a "strong-buy" rating in a research note on Thursday, July 17th. Raymond James Financial reduced their price objective on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a research note on Friday. Barclays upped their price objective on shares of Abbott Laboratories from $158.00 to $159.00 and gave the company an "overweight" rating in a research note on Thursday, April 17th. Wells Fargo & Company decreased their price target on shares of Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating for the company in a report on Friday. Finally, Leerink Partners started coverage on shares of Abbott Laboratories in a report on Monday, June 16th. They set a "market perform" rating and a $143.00 price target for the company. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $144.47.
Check Out Our Latest Report on ABT
About Abbott Laboratories
(
Free Report)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Featured Articles
Before you consider Abbott Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.
While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
